ZLAB vs CAN

For growth investors, Canaan Inc.

(CAN) is the stronger pick with 96. 7% revenue growth year-over-year, versus 15. 3% for Zai Lab Limited (ZLAB). Analysts rate Zai Lab Limited (ZLAB) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Zai Lab Limited (ZLAB) delivered a total return of -86.

5%, compared to -92. 0% for Canaan Inc. (CAN). Over 10 years, the gap is even starker: ZLAB returned -24. 8% versus CAN's -89. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zai Lab Limited (ZLAB) is the lower-risk stock at 1.

21β versus Canaan Inc. 's 4. 41β — meaning CAN is approximately 264% more volatile than ZLAB relative to the S&P 500. On balance sheet safety, Canaan Inc. (CAN) carries a lower debt/equity ratio of 13% versus 31% for Zai Lab Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Canaan Inc.

(CAN) is pulling ahead at 96. 7% versus 15. 3% for Zai Lab Limited (ZLAB). On earnings-per-share growth, the picture is similar: Canaan Inc. grew EPS 51. 1% year-over-year, compared to 38. 5% for Zai Lab Limited. Over a 3-year CAGR, ZLAB leads at 28. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zai Lab Limited (ZLAB) is the more profitable company, earning -38.

1% net margin versus -39. 7% for Canaan Inc. — meaning it keeps -38. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CAN leads at -21. 2% versus -49. 9% for ZLAB. At the gross margin level — before operating expenses — ZLAB leads at 58. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Zai Lab Limited (ZLAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

21)). Canaan Inc. (CAN) carries a higher beta of 4. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ZLAB: -24. 8%, CAN: -89. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZLAB (Healthcare) and CAN (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.